-
Mashup Score: 3Myeloma - Cancer Stat Facts - 3 month(s) ago
Myeloma statistics
Source: seer.cancer.govCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9
Program: Oral and Poster Abstracts Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III Hematology Disease Topics & Pathways: Research, Translational Research, Non-Biological therapies, drug development, Therapies Pankaj Kumar Singh, PhD 1 *, Frances N. Cervoni Curet, MD 1 *, Cody T. Clayhold, BA 2 *, Isere Kuiatse, PhD 1 *, Wei Tan 1 *, Marco Meloni, PhD 3 *, Monsif Bouaboula, PhD 3 *, Kamlesh Bisht, PhD 3 *, Helgi J. Van de Velde, MD, PhD 3, Marielle Chiron, PhD
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Myeloma Panel Discusses 3 FDA-Approved Bispecific Agents: Talquetamab, Teclistamab, Elranatamab | Blood Cancers Today - 3 month(s) ago
The panel discussed the FDA-approved bispecific agents for myeloma and how the options performed in clinical trials.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
@TischCancer @IcahnMountSinai β°Here's video #4! In this panel, @TomBmt133 (@UCSFCancer), @AjayNookaMD (@EmoryMedicine), @AjaiChari (@UCSF), & @ADispenzieri (@MayoClinic) discuss @US_FDA-approved bispecific agents for #myeloma and how they performed in clinical trials. πΊWatch here! https://t.co/l2PJ8Bb0vc https://t.co/dA5qXyc9Jj
-
-
Mashup Score: 37Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population - PubMed - 3 month(s) ago
Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition of multiple myeloma with few known risk factors. The emergence of mass spectrometry (MS) for the detection of MGUS has provided new opportunities to evaluate its risk factors. 2628 individuals at elevated risk for β¦
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13First individualized predictive model for multiple myeloma treatment - 3 month(s) ago
Multiple myeloma remains challenging to treat. New therapeutic advances have improved outcomes, but selecting the right treatment for a patient can be complex because the disease can vary drastically …
Source: medicalxpress.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
National Institutes of Health, National Cancer Institute, Bristol Myers Squibb, Celgene, Leukemia and Lymphoma Society.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
In this study, we present a present a novel, three-gene expression signature that predicts selinexor response in MM. This signature has important clinical relevance as it could identify patients with cancer who are most likely to benefit from treatment with selinexor-based therapy.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11
Karyopharm Therapeutics.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
1/2 When you have a Phase 3 trial with superior PFS in relapsed/refractory #myeloma (https://t.co/sPgYplSbPp) & subsequent Abstracts w/ good OS trends (yes, mature data would be nice), tough to defend statement that "Selinexor doesnβt help patients as a whole. It hurts them." https://t.co/k6Vz9pHTlG https://t.co/49bzXszrYK
-
-
Mashup Score: 54
Blood Cancer Journal – Mode of progression in smoldering multiple myeloma: a study of 406 patients
Source: www.nature.comCategories: General Medicine News, Partners & KOLsTweet-
Imp. paper by @VincentRK ππ‘ ππ on mode of progression in a π¦π¨πππ«π§ ππ¨π‘π¨π«π of patients with smoldering #myeloma! Helpful for initial discussion in patients with ππ’π π‘-ππ’π¬π€ πππ re. clinical trials vs active surveillance vs Len https://t.co/PrlIR0u1S9 1/4 https://t.co/2ch8ULw3w3
-
-
Mashup Score: 1Elranatamab Sustains Promising Responses with Less-Frequent Dosing in Myeloma | Blood Cancers Today - 4 month(s) ago
Elranatamab yielded deep and durable responses in patients with relapsed or refractory multiple myeloma, even after switching to a biweekly dosing schedule.
Source: bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet
The rate of new cases for #Myeloma, a cancer that forms in blood plasma, have not changed much from 2010-19. The death rate fell by 1.3% each year from 2011-20. Visit our Cancer Stat Facts sheet to learn more: https://t.co/pYtpgFoOi1 https://t.co/xx3U9OcBtU